Lyell Immunopharma, Inc. - LYEL STOCK NEWS

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a leader in T-cell reprogramming, announced participation in the BofA Securities 2022 Healthcare Conference on May 11 at 5:20 pm PT. The management team will engage in a fireside chat that can be accessed via a live webcast on the company's investor relations page. A replay will be available for 90 days after the event. Lyell focuses on overcoming challenges in adoptive T-cell therapy, utilizing proprietary technologies Gen-R and Epi-R to enhance T-cell functionality for combating solid tumors.

Lyell Immunopharma (Nasdaq: LYEL) announced two abstracts accepted for poster presentations at the 25th Annual Meeting of the American Society of Gene & Cell Therapy, from May 16 to May 19, 2022. The presentations will showcase preclinical data on LYL797 and LYL132, both in Phase 1 trials, focusing on Gen-R and Epi-R technologies that enhance T-cell performance against solid tumors. LYL797 targets ROR1-positive cancers, while LYL132 targets NY-ESO-1 expressing tumors. The aim is to improve T-cell durability and anti-tumor effectiveness.

Lyell Immunopharma (Nasdaq: LYEL) reported its 2021 financial results, highlighting a net loss of $250.2 million. Cash, equivalents, and marketable securities totaled $898 million as of Dec 31, 2021, supporting their cell therapy pipeline. The company received FDA clearance for two INDs and is initiating clinical trials for therapies targeting solid tumors. Key R&D expenses decreased to $138.7 million from $182.2 million in 2020. The team was strengthened with new executive appointments. Positive long-term outlook with cash expected to sustain operations until at least 2025.

Lyell Immunopharma has announced that its investigational LYL797, a ROR1 CAR T-cell therapy, will be presented at the AACR 2022 Annual Meeting from April 8-13 in New Orleans. The therapy employs advanced T-cell reprogramming technologies aimed at treating solid tumors. Preclinical data will be highlighted, showcasing Gen-R and Epi-R technologies that enhance T-cell durability and functionality. The poster presentation is scheduled for April 12, featuring Spencer Park, PhD.

LYL797 has received FDA clearance for Phase 1 clinical trials.

Lyell Immunopharma, Inc. (Nasdaq: LYEL) has appointed Gary Lee, Ph.D., as its new Chief Scientific Officer. Dr. Lee brings over a decade of experience in translational cell and gene therapy, aiming to advance the company’s research pipeline. This strategic move reflects Lyell's commitment to developing a multi-modality cell therapy pipeline using its innovative T-cell reprogramming technologies. Concurrently, Nick Restifo will transition to a scientific advisor role, continuing to support the company's programs.

Lyell Immunopharma announced the FDA has cleared an IND application to start a Phase 1 clinical trial for LYL132, a T-cell receptor therapy targeting NY-ESO-1 in patients with solid tumors. This therapy utilizes Lyell’s Epi-R technology, aimed at overcoming barriers in adoptive cell therapy by promoting T cell properties of durable stemness. The clinical trial will focus on advanced synovial sarcoma and myxoid/round cell liposarcoma. This clearance marks a significant milestone for Lyell, indicating progress in their collaboration with GSK and their commitment to cancer drug development.

Lyell Immunopharma, a T-cell reprogramming company, will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:00 PM ET. The company plans to showcase its diverse pipeline, including LYL797, a CAR T-cell therapy for solid tumors, with patient screening expected by Q1 2022 and preliminary data in 2023. Additionally, Lyell will discuss its innovative technologies, Gen-R™ and Epi-R™, enhancing T-cell functions. The newly established LyFE™ Manufacturing Center will ensure quality and efficiency in cell product production.

Lyell Immunopharma has received FDA clearance for its IND application to begin a Phase 1 clinical trial for LYL797, a novel CAR T-cell therapy targeting ROR1 in solid tumors. Expected to start screening patients by Q1 2022, LYL797 aims to tackle T-cell exhaustion and enhance durable stemness using Lyell's innovative technologies, Gen-R and Epi-R. The trial will initially focus on patients with relapsed/refractory triple-negative breast cancer (TNBC) and later include those with non-small cell lung cancer (NSCLC). Initial data is anticipated in 2023.

Lyell Immunopharma has announced the commissioning of its LyFE Manufacturing Center in Bothell, WA, complying with FDA's cGMP standards. The facility, operational since April 2021, is designed to produce cell products at scale for upcoming clinical trials, including CAR, TIL, and TCR programs. It incorporates advanced data analytics for real-time monitoring and process optimization, supported by a partnership with Amazon Web Services. This infrastructure is pivotal in Lyell's efforts to address challenges in T-cell therapy, aiming for effective treatments for solid tumors.